Boston Scientific lands in Dallas as FDA panel reviews heart device

Boston Scientific flew from Morristown Municipal Airport to Dallas Love Field on the evening of May 27, a three-hour-and-48-minute hop in its Bombardier Challenger 650, tail number N650BS. The flight touched down just before midnight local time, following a series of recent trips that have shuttled the company’s executives between Massachusetts, New Jersey, and Minnesota.

The same week, the U.S. Food and Drug Administration’s Circulatory System Devices Panel is scheduled to review Boston Scientific’s premarket approval application for a novel left atrial appendage closure device, per an FDA notice published May 23. Dallas is home to the company’s regional cardiac rhythm management offices and a key clinical trial site, making it a logical destination for last-minute regulatory briefings or investigator meetings ahead of the June 1 panel vote.

The flight pattern shows Boston Scientific’s Challenger 650 has been unusually active this month, with trips to Minneapolis, Paris, and New Jersey. The Dallas arrival fits a broader push to secure approvals for its cardiology pipeline — a business segment that generated roughly $4.5 billion in revenue last year, according to the company’s most recent annual filing.